



Patient Ref. No. 251000000168743



CLIENT CODE : C000049066

Cert. No. MC-5333

## CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)  
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

SRL Ltd

C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,  
Tonk Road  
JAIPUR, 302015  
Rajasthan, INDIAJAIPUR 302017  
RAJASTHAN INDIA  
9314660100

PATIENT NAME : AMARTI DEVI

PATIENT ID : AMARF241293251

ACCESSION NO : 0251VL002080 AGE : 29 Years SEX : Female

ABHA NO :

DRAWN : 24/12/2022 09:35:00

RECEIVED : 24/12/2022 11:55:15

REPORTED : 25/12/2022 15:49:35

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212240027

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE****BLOOD COUNTS, EDTA WHOLE BLOOD**

HEMOGLOBIN (HB)	14.2	12.0 - 15.0	g/dL
METHOD : CYANIDE FREE DETERMINATION			
RED BLOOD CELL (RBC) COUNT	4.70	3.8 - 4.8	mil/ $\mu$ L
METHOD : ELECTRICAL IMPEDANCE			
WHITE BLOOD CELL (WBC) COUNT	7.80	4.0 - 10.0	thou/ $\mu$ L
METHOD : ELECTRICAL IMPEDANCE			
PLATELET COUNT	263	150 - 410	thou/ $\mu$ L
METHOD : ELECTRONIC IMPEDANCE			

**RBC AND PLATELET INDICES**

HEMATOCRIT (PCV)	43.1	36 - 46	%
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR VOLUME (MCV)	92.0	83 - 101	fL
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	30.3	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	33.0	31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	11.7	11.6 - 14.0	%
METHOD : CALCULATED PARAMETER			
MENTZER INDEX	19.6		
MEAN PLATELET VOLUME (MPV)	9.3	6.8 - 10.9	fL
METHOD : CALCULATED PARAMETER			

**WBC DIFFERENTIAL COUNT**

NEUTROPHILS	56	40 - 80	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
LYMPHOCYTES	35	20 - 40	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
MONOCYTES	05	2 - 10	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
EOSINOPHILS	04	1 - 6	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
BASOPHILS	00	0 - 2	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			



Scan to View Details



Scan to View Report



Patient Ref. No. 251000000168743



CLIENT CODE : C000049066

Cert. No. MC-5333

## CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)  
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

SRL Ltd

C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,  
Tonk Road  
JAIPUR, 302015  
Rajasthan, INDIAJAIPUR 302017  
RAJASTHAN INDIA  
9314660100

PATIENT NAME : AMARTI DEVI

PATIENT ID : AMARF241293251

ACCESSION NO : 0251VL002080 AGE : 29 Years SEX : Female

ABHA NO :

DRAWN : 24/12/2022 09:35:00

RECEIVED : 24/12/2022 11:55:15

REPORTED : 25/12/2022 15:49:35

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212240027

Test Report Status	Final	Results	Biological Reference Interval	Units
ABSOLUTE NEUTROPHIL COUNT		4.37	2.0 - 7.0	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT		2.73	1.0 - 3.0	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT		0.39	0.2 - 1.0	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT		0.31	0.02 - 0.50	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT		0	Low 0.02 - 0.10	thou/ $\mu$ L
NEUTROPHIL LYMPHOCYTE RATIO (NLR)		1.6		
<b>* ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD</b>				
E.S.R		09	0 - 20	mm at 1 hr
METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"				
<b>GLUCOSE FASTING, FLUORIDE PLASMA</b>				
FBS (FASTING BLOOD SUGAR)		90	74 - 99	mg/dL
METHOD : GLUCOSE OXIDASE				
<b>GLYCOSYLATED HEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD</b>				
HBA1C		5.2	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
METHOD : HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)				
ESTIMATED AVERAGE GLUCOSE (EAG)		102.5	< 116.0	mg/dL
METHOD : CALCULATED PARAMETER				
<b>GLUCOSE, POST-PRANDIAL, PLASMA</b>				
PPBS (POST PRANDIAL BLOOD SUGAR)		110	70 - 140	mg/dL
METHOD : GLUCOSE OXIDASE				
<b>LIPID PROFILE, SERUM</b>				
CHOLESTEROL, TOTAL		238	High < 200 Desirable 200 - 239 Borderline High > / = 240 High	mg/dL
METHOD : CHOLESTEROL OXIDASE				



Scan to View Details



Scan to View Report



Patient Ref. No. 251000000168743



CLIENT CODE : C000049066

Cert. No. MC-5333

## CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)  
AAKRITI LABS PVT LTD. A-430, AGRASEN MARGSRL Ltd  
C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,  
Tonk Road  
JAIPUR, 302015  
Rajasthan, INDIAJAIPUR 302017  
RAJASTHAN INDIA  
9314660100

PATIENT NAME : AMARTI DEVI

PATIENT ID : AMARF241293251

ACCESSION NO : 0251VL002080 AGE : 29 Years SEX : Female ABHA NO :

DRAWN : 24/12/2022 09:35:00 RECEIVED : 24/12/2022 11:55:15 REPORTED : 25/12/2022 15:49:35

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212240027

Test Report Status	Final	Results	Biological Reference Interval	Units
TRIGLYCERIDES		98	< 150 Normal 150 - 199 Borderline High 200 - 499 High >=500 Very High	mg/dL
METHOD : LIPASE/GPO-PAP NO CORRECTION				
HDL CHOLESTEROL		49	< 40 Low >=60 High	mg/dL
METHOD : DIRECT CLEARANCE METHOD				
CHOLESTEROL LDL		<b>169</b>	<b>High</b> < 100 Optimal 100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High >= 190 Very High	mg/dL
NON HDL CHOLESTEROL		<b>189</b>	<b>High</b> Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
METHOD : CALCULATED PARAMETER				
CHOL/HDL RATIO		<b>4.9</b>	<b>High</b> 3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO		<b>3.4</b>	<b>High</b> 0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	
VERY LOW DENSITY LIPOPROTEIN		19.6	</= 30.0	mg/dL
<b>LIVER FUNCTION PROFILE, SERUM</b>				
BILIRUBIN, TOTAL		0.61	0 - 1	mg/dL
METHOD : DIAZO WITH SULPHANILIC ACID				
BILIRUBIN, DIRECT		0.19	0.00 - 0.25	mg/dL
METHOD : DIAZO WITH SULPHANILIC ACID				
BILIRUBIN, INDIRECT		0.42	0.1 - 1.0	mg/dL
METHOD : CALCULATED PARAMETER				
TOTAL PROTEIN		8.1	6.4 - 8.2	g/dL
METHOD : BIURET REACTION, END POINT				



Scan to View Details



Scan to View Report



Patient Ref. No. 25100000168743



CLIENT CODE : C000049066

Cert. No. MC-5333

## CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)  
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

SRL Ltd

C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,  
Tonk Road  
JAIPUR, 302015  
Rajasthan, INDIAJAIPUR 302017  
RAJASTHAN INDIA  
9314660100

PATIENT NAME : AMARTI DEVI

PATIENT ID : AMARF241293251

ACCESSION NO : 0251VL002080 AGE : 29 Years SEX : Female ABHA NO :

DRAWN : 24/12/2022 09:35:00 RECEIVED : 24/12/2022 11:55:15 REPORTED : 25/12/2022 15:49:35

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212240027

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

ALBUMIN	4.5	High	3.8 - 4.4	g/dL
METHOD : BROMOCRESOL GREEN				
GLOBULIN	3.6		2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER				
ALBUMIN/GLOBULIN RATIO	1.3		1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER				
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	27		0 - 31	U/L
METHOD : TRIS BUFFER NO P5P IFCC / SFBC 37° C				
ALANINE AMINOTRANSFERASE (ALT/SGPT)	14		0 - 31	U/L
METHOD : TRIS BUFFER NO P5P IFCC / SFBC 37° C				
ALKALINE PHOSPHATASE	63		39 - 117	U/L
METHOD : AMP OPTIMISED TO IFCC 37° C				
GAMMA GLUTAMYL TRANSFERASE (GGT)	16		7 - 32	U/L
METHOD : GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IFCC) 37° C				
LACTATE DEHYDROGENASE	367		230 - 460	U/L
METHOD : GERMAN METHODS 37° C				
<b>BLOOD UREA NITROGEN (BUN), SERUM</b>				
BLOOD UREA NITROGEN	8		5.0 - 18.0	mg/dL
METHOD : UREASE KINETIC				
<b>CREATININE, SERUM</b>				
CREATININE	0.81		0.6 - 1.2	mg/dL
METHOD : ALKALINE PICRATE NO DEPROTEINIZATION				
<b>BUN/CREAT RATIO</b>				
BUN/CREAT RATIO	9.88			
METHOD : CALCULATED PARAMETER				
<b>URIC ACID, SERUM</b>				
URIC ACID	4.1		2.4 - 5.7	mg/dL
METHOD : URICASE PEROXIDASE WITH ASCORBATE OXIDASE				
<b>TOTAL PROTEIN, SERUM</b>				
TOTAL PROTEIN	8.1		6.4 - 8.3	g/dL
METHOD : BIURET REACTION, END POINT				
<b>ALBUMIN, SERUM</b>				
ALBUMIN	4.5	High	3.8 - 4.4	g/dL
METHOD : BROMOCRESOL GREEN				
<b>GLOBULIN</b>				



Scan to View Details



Scan to View Report



Patient Ref. No. 251000000168743



CLIENT CODE : C000049066

Cert. No. MC-5333

## CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)  
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

SRL Ltd

C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,  
Tonk Road  
JAIPUR, 302015  
Rajasthan, INDIAJAIPUR 302017  
RAJASTHAN INDIA  
9314660100

PATIENT NAME : AMARTI DEVI

PATIENT ID : AMARF241293251

ACCESSION NO : 0251VL002080 AGE : 29 Years SEX : Female ABHA NO :

DRAWN : 24/12/2022 09:35:00 RECEIVED : 24/12/2022 11:55:15 REPORTED : 25/12/2022 15:49:35

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212240027

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

GLOBULIN	3.6	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER			
<b>ELECTROLYTES (NA/K/CL), SERUM</b>			
SODIUM, SERUM	139.9	137 - 145	mmol/L
METHOD : ION-SELECTIVE ELECTRODE			
POTASSIUM, SERUM	4.71	3.6 - 5.0	mmol/L
METHOD : ION-SELECTIVE ELECTRODE			
CHLORIDE, SERUM	102.9	98 - 107	mmol/L
METHOD : ION-SELECTIVE ELECTRODE			

**Interpretation(s)****PHYSICAL EXAMINATION, URINE**

COLOR PALE YELLOW

METHOD : GROSS EXAMINATION

APPEARANCE CLEAR

METHOD : GROSS EXAMINATION

**CHEMICAL EXAMINATION, URINE**

PH 5.5 4.7 - 7.5

METHOD : DOUBLE INDICATOR PRINCIPLE

SPECIFIC GRAVITY 1.005 1.003 - 1.035

METHOD : IONIC CONCENTRATION METHOD

PROTEIN NOT DETECTED NOT DETECTED

METHOD : PROTEIN ERROR OF INDICATORS WITH REFLECTANCE

GLUCOSE NOT DETECTED NOT DETECTED

METHOD : GLUCOSE OXIDASE PEROXIDASE / BENEDICTS

KETONES NOT DETECTED NOT DETECTED

METHOD : SODIUM NITROPRUSSIDE REACTION

BLOOD NOT DETECTED NOT DETECTED

METHOD : PEROXIDASE ANTI PEROXIDASE

BILIRUBIN NOT DETECTED NOT DETECTED

METHOD : DIPSTICK

UROBILINOGEN NORMAL NORMAL

METHOD : EHRlich REACTION REFLECTANCE

NITRITE NOT DETECTED NOT DETECTED

METHOD : NITRATE TO NITRITE CONVERSION METHOD

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED



Scan to View Details



Scan to View Report



Patient Ref. No. 251000000168743



CLIENT CODE : C000049066

Cert. No. MC-5333

## CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)  
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

SRL Ltd

C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,  
Tonk Road  
JAIPUR, 302015  
Rajasthan, INDIAJAIPUR 302017  
RAJASTHAN INDIA  
9314660100

PATIENT NAME : AMARTI DEVI

PATIENT ID : AMARF241293251

ACCESSION NO : 0251VL002080 AGE : 29 Years SEX : Female ABHA NO :

DRAWN : 24/12/2022 09:35:00 RECEIVED : 24/12/2022 11:55:15 REPORTED : 25/12/2022 15:49:35

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212240027

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION			
PUS CELL (WBC'S)	1-2	0-5	/HPF
METHOD : DIPSTICK, MICROSCOPY			
EPITHELIAL CELLS	2-3	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
CASTS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
CRYSTALS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
BACTERIA	NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			
YEAST	NOT DETECTED	NOT DETECTED	

## Interpretation(s)

## THYROID PANEL, SERUM

T3	118.9	60.0 - 181.0	ng/dL
METHOD : CHEMILUMINESCENCE			
T4	5.90	4.5 - 10.9	µg/dL
METHOD : CHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	1.696	0.550 - 4.780	µIU/mL
METHOD : CHEMILUMINESCENCE			

## Interpretation(s)

## PAPANICOLAOU SMEAR

TEST METHOD SAMPLE NOT RECEIVED

## PHYSICAL EXAMINATION, STOOL

COLOUR SAMPLE NOT RECEIVED

METHOD : GROSS EXAMINATION

## \* ABO GROUP &amp; RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE O

METHOD : TUBE AGGLUTINATION

RH TYPE POSITIVE

METHOD : TUBE AGGLUTINATION



Scan to View Details



Scan to View Report



Patient Ref. No. 251000000168743



CLIENT CODE : C000049066

Cert. No. MC-5333

## CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)  
AAKRITI LABS PVT LTD. A-430, AGRASEN MARGSRL Ltd  
C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,  
Tonk Road  
JAIPUR, 302015  
Rajasthan, INDIAJAIPUR 302017  
RAJASTHAN INDIA  
9314660100

PATIENT NAME : AMARTI DEVI

PATIENT ID : AMARF241293251

ACCESSION NO : 0251VL002080 AGE : 29 Years SEX : Female ABHA NO :

DRAWN : 24/12/2022 09:35:00 RECEIVED : 24/12/2022 11:55:15 REPORTED : 25/12/2022 15:49:35

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212240027

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia (>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

## ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

## TEST INTERPRETATION

**Increase in:** Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr (62 if anemic) and in second trimester (0-70 mm /hr (95 if anemic). ESR returns to normal 4th week post partum.

**Decreased in:** Polycythemia vera, Sickle cell anemia

## LIMITATIONS

**False elevated ESR :** Increased fibrinogen, Drugs (Vitamin A, Dextran etc), Hypercholesterolemia

**False Decreased :** Poikilocytosis, (Sickle Cells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

## REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

## GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

## Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

## Decreased in

Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g., galactosemia), Drugs- insulin, ethanol, propranolol; sulfonureas, tolbutamide, and other oral hypoglycemic agents.

## NOTE:

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycaemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months.

3. eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7



Scan to View Details



Scan to View Report



**CLIENT CODE :** C000049066

Cert. No. MC-5333

**CLIENT'S NAME AND ADDRESS :**

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)  
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

SRL Ltd  
C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,  
Tonk Road  
JAIPUR, 302015  
Rajasthan, INDIA

JAIPUR 302017  
RAJASTHAN INDIA  
9314660100

**PATIENT NAME : AMARTI DEVI**

**PATIENT ID : AMARF241293251**

**ACCESSION NO : 0251VL002080**    **AGE :** 29 Years    **SEX :** Female    **ABHA NO :**

**DRAWN :** 24/12/2022 09:35:00    **RECEIVED :** 24/12/2022 11:55:15    **REPORTED :** 25/12/2022 15:49:35

**REFERRING DOCTOR :** SELF

**CLIENT PATIENT ID :** 012212240027

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**HbA1c Estimation can get affected due to :**

- I. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin).
- III. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.
- IV. Interference of hemoglobinopathies in HbA1c estimation is seen in
  - a. Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
  - b. Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
  - c. HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels result from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis. Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

**BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels** include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

**Causes of decreased level** include Liver disease, SIADH.

**CREATININE, SERUM-Higher than normal level** may be due to:

- Blockage in the urinary tract
- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia), or high blood pressure caused by pregnancy (preeclampsia)

**Lower than normal level** may be due to:

- Myasthenia Gravis
- Muscular dystrophy

**URIC ACID, SERUM-Causes of Increased levels:** Dietary (High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome

**Causes of decreased levels:** Low Zinc intake, OCP, Multiple Sclerosis

**TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum.. Protein in the plasma is made up of albumin and globulin**

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

**ALBUMIN, SERUM-**



Scan to View Details



Scan to View Report





Patient Ref. No. 251000000168743



CLIENT CODE : C000049066

Cert. No. MC-5333

## CLIENT'S NAME AND ADDRESS :

SRL JAIPUR WELLNESS CORPORATE WALK IN (CASH)  
AAKRITI LABS PVT LTD. A-430, AGRASEN MARGSRL Ltd  
C/o Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod,  
Tonk Road  
JAIPUR, 302015  
Rajasthan, INDIAJAIPUR 302017  
RAJASTHAN INDIA  
9314660100

PATIENT NAME : AMARTI DEVI

PATIENT ID : AMARF241293251

ACCESSION NO : 0251VL002080 AGE : 29 Years SEX : Female ABHA NO :

DRAWN : 24/12/2022 09:35:00 RECEIVED : 24/12/2022 11:55:15 REPORTED : 25/12/2022 15:49:35

REFERRING DOCTOR : SELF

CLIENT PATIENT ID : 012212240027

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ABO GROUP &amp; RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

**\*\*End Of Report\*\***

Please visit [www.srlworld.com](http://www.srlworld.com) for related Test Information for this accession  
TEST MARKED WITH '\*' ARE OUTSIDE THE NABL ACCREDITED SCOPE OF THE LABORATORY.

**Dr. Abhishek Sharma**  
Consultant Microbiologist

**Dr. Akansha Jain**  
Consultant Pathologist



Scan to View Details



Scan to View Report

NAME	MRS AMARTI MEENA	AGE	29Y	SEX	FEMALE
REF BY	MEDIWHEEL	DATE	24/12/2022	REG NO	

## ECHOCARDIOGRAM REPORT

WINDOW- POOR/ADEQUATE/GOODVALVE

MITRAL	NORMAL	TRICUSPID	NORMAL
AORTIC	NORMAL	PULMONARY	NORMAL

### 2D/M-MOD

IVSD mm	22.0	IVSS mm	7.8	AORTA mm	22.0
LVID mm	23.0	LVIS mm	22.9	LA mm	22.9
LVPWD mm	10.1	LVPWS mm	7.8	EF%	60%

### CHAMBERS

LA	NORMAL	RA	NORMAL
LV	NORMAL	RV	NORMAL
PERICARDIUM	NORMAL		

### DOPPLER STUDY MITRAL

PEAK VELOCITY m/s E/A	0.77/0.61	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
MVA cm2 (PLANITMETER)		MVA cm2 (PHT)	
MR			

### AORTIC

PEAK VELOCITY m/s	0.98	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
AR			

### TRICUSPID

PEAK VELOCITY m/s	0.92	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
TR		PASP mmHg	

### PULMONARY

PEAK VELOCITY m/s	1.42	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
PR		RVEDP mmHg	

### IMPRESSION

- NORMAL LV SYSTOLIC & DIASTOLIC FUNCTION
- NO RWMA LVEF 60%
- NORMAL RV FUNCTION
- NORMAL CHAMBER DIMENSIONS
- NORMAL VALVULAR ECHO
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- IVC NORMAL

CONCLUSION : FAIR LV FUNCTION.

  
Cardiologist



Name : Ms. AMARTI DEVI  
Age/Gender: 29 Y 9 M 10 D/Female  
Patient ID : 012212240027  
BarcodeNo : 10071477  
Referred By : Self

Registration No: 48908  
Registered : 24/Dec/2022 09:35AM  
Analysed : 25/Dec/2022 11:44AM  
Reported : 25/Dec/2022 11:44AM  
Panel : Medi Wheel (ArcoFemi  
Healthcare Ltd)

## DIGITAL X-RAY CHEST PA VIEW

Soft tissue shadow and bony cages are normal.  
Trachea is central.  
Bilateral lung field and both CP angle are clear.  
Domes of diaphragm are normally placed.  
Transverse diameter of heart appears with normal limits.

**IMPRESSION:- NO OBVIOUS ABNORMALITY DETECTED.**

\*\*\* End Of Report \*\*\*

Page 1 of



Dr. Neera Mehta  
M.B.B.S.,D.M.R.D.

RMCNO.005807/14853



Name : Ms. AMARTI DEVI  
Age/Gender: 29 Y 9 M 10 D/Female  
Patient ID : 012212240027  
BarcodeNo : 10071477  
Referred By : Self

Registration No: 48908  
Registered : 24/Dec/2022 09:35AM  
Analysed : 24/Dec/2022 12:59PM  
Reported : 24/Dec/2022 12:59PM  
Panel : Medi Wheel (ArcoFemi  
Healthcare Ltd)


### USG: WHOLE ABDOMEN (Female)

- LIVER** : Is normal in size, shape and echogenicity.  
The IHBR and hepatic radicals are not dilated.  
No evidence of focal echopoor/echorich lesion seen.  
Portal vein diameter and Common bile duct normal in size
- GALL** : Is normal in size, shape and echotexture. Walls are smooth and  
**BLADDER** regular with normal thickness. There is no evidence of cholelithiasis.
- PANCREAS**: Is normal in size, shape and echotexture. Pancreatic duct is not dilated.  
**SPLEEN** : Is normal in size, shape and echogenicity. Spleenic hilum is not dilated.
- KIDNEYS** : Bilateral Kidneys are normal in size, shape and echotexture,  
corticomedullary differentiation is fair and ratio appears normal.  
Pelvi calyceal system is normal. No evidence of hydronephrosis/ nephrolithiasis.
- URINARY** : Bladder is partially filled as patient not willing to hold urine.  
**BLADDER** : Pre void vol: 60 ml
- UTERUS** : Uterus and ovaries could not be seen due to partially filled bladder.
- SPECIFIC** : No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity.  
NO evidence of lymphadenopathy or mass lesion in retroperitoneum.  
Visualized bowel loop appear normal. Great vessels appear normal.
- IMPRESSION**: Ultra Sonography findings are suggestive of: **NORMAL STUDY.**

\*\*\* End Of Report \*\*\*

Page 1 of 1



  
Dr. Neera Mehta  
M.B.B.S., D.M.R.D.  
RMCNO.005807/14853

AAKRITI LABS PVT. LTD.

MEDIPURHEL

29/10/22

Patient Information

ID:

Name: - MRS. AMRITI MEENA

Age: ~~29~~ 29 yrs Gender: - F

Height: - cms Weight: - Kg

BP: - Smoker: -

Time/Date: 24:58:19 29/10/22

ECG Settings

Pacing Mode: - ATR0

Gain: - 10 mm/mV


Speed: - 25 mm/Sec

Filter: - 35 Hz

Notch: - ON

Rhythm Lead: - V2

ALLENGERS PISCES-A-103 (Ver-1.9)



AccoW C

Observations :-


HR :- 69bpm  
R-R :- 868ms  
P-R :- 102ms  
QRS :- 66ms  
QT :- 381ms  
QTc :- 411ms  
P Axis :- 53°  
R Axis :- 57°  
T Axis :- 35°

Indications :-

HR Normal  
Normal Sinus Rhythm  
Normal Electric Heart Axis

Remarks :-

Unconfirmed report



ECG - NSR wave

DR. ARIF IJUSSAIN KHAN  
MDS PGDCG  
RMC NUMBER 023361